Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858871 · ClinicalTrials.gov registry record · Phase 3
First Line Hepato Cellular Carcinoma (HCC)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,714
- Enrollment target
NCT00858871: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00858871 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,714 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00858871, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,714 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Interventions
- DRUG Placebo
- DRUG Sorafenib
- DRUG Brivanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,714 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
What the finished NCT00858871 record still lists
NCT00858871 is an interventional study that assigns participants to a tested intervention. Its 1,714 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00858871 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00858871 about?
NCT00858871 is a clinical study titled "First Line Hepato Cellular Carcinoma (HCC)". The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
What is the current status of trial NCT00858871?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,714 participants. The study started on 2009-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00858871?
The interventions under investigation include: Placebo (DRUG), Sorafenib (DRUG), Brivanib (DRUG).
Who is sponsoring clinical trial NCT00858871?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00858871's enrollment target sits among peer trials
1,714 130th of 2000 higher than 1,870 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia